Drug intelligence / Profile preview

188Re-MN-16ET + lipiodol

Development stage: Unknown
Lead developer: National Atomic Research Institute
Modality: Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intra-arterial

Overview

**188Re-MN-16ET + lipiodol** is a combination radiopharmaceutical drug consisting of the rhenium-188 labeled chelate 188Re-MN-16ET dissolved in lipiodol, an iodized oil. The agent is designed for targeted **radiotherapy of hepatocellular carcinoma (HCC)**. 188Re-MN-16ET, made by labeling the tetradentate ligand MN-16ET with rhenium-188, offers high radiochemical purity (>90%) and solubility in lipiodol, which enables preferential retention in liver tumors following arterial injection. The delivered β-radiation (and some gamma emission) from rhenium-188 induces cytotoxicity in tumor tissues, exploiting the selective accumulation of lipiodol in hepatic tumors. Developed and studied primarily in preclinical rat models, this radiotherapeutic agent enables targeted internal irradiation for hepatoma with limited systemic distribution.

Other names: rhenium-188 MN-16ET lipiodolrhenium188 MN-16ET lipiodolrhenium 188 MN-16ET lipiodolRe-188 MN-16ET lipiodolRe188 MN-16ET lipiodolRe 188 MN-16ET lipiodol188Re-MN-16ET lipiodol

Targets

DNA

Beyond the preview

Go deeper on 188Re-MN-16ET + lipiodol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 188Re-MN-16ET + lipiodol.

Explore the full profile